WO2022231533A1 - Process for the preparation of sterilized suspensions for the inhalation by nebulization - Google Patents
Process for the preparation of sterilized suspensions for the inhalation by nebulization Download PDFInfo
- Publication number
- WO2022231533A1 WO2022231533A1 PCT/TR2021/050410 TR2021050410W WO2022231533A1 WO 2022231533 A1 WO2022231533 A1 WO 2022231533A1 TR 2021050410 W TR2021050410 W TR 2021050410W WO 2022231533 A1 WO2022231533 A1 WO 2022231533A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sorbitan
- polyoxyethylene
- process according
- dispersing
- mixture
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 57
- 230000008569 process Effects 0.000 title claims abstract description 43
- 239000000725 suspension Substances 0.000 title claims abstract description 30
- 238000002663 nebulization Methods 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 20
- 239000000203 mixture Substances 0.000 claims description 64
- 239000002270 dispersing agent Substances 0.000 claims description 39
- 239000000375 suspending agent Substances 0.000 claims description 39
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 24
- -1 polyoxyethylene Polymers 0.000 claims description 22
- 238000002156 mixing Methods 0.000 claims description 19
- 239000006172 buffering agent Substances 0.000 claims description 16
- 230000001954 sterilising effect Effects 0.000 claims description 16
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 14
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 239000007951 isotonicity adjuster Substances 0.000 claims description 13
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 12
- 239000003862 glucocorticoid Substances 0.000 claims description 12
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 12
- 229920000053 polysorbate 80 Polymers 0.000 claims description 12
- 235000002639 sodium chloride Nutrition 0.000 claims description 12
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 8
- 229920001219 Polysorbate 40 Polymers 0.000 claims description 8
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 229960002714 fluticasone Drugs 0.000 claims description 8
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 claims description 8
- 229960000289 fluticasone propionate Drugs 0.000 claims description 8
- 239000000787 lecithin Substances 0.000 claims description 8
- 235000010445 lecithin Nutrition 0.000 claims description 8
- 229940067606 lecithin Drugs 0.000 claims description 8
- 229940068977 polysorbate 20 Drugs 0.000 claims description 8
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 8
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 8
- 239000001593 sorbitan monooleate Substances 0.000 claims description 8
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 8
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 7
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 239000008215 water for injection Substances 0.000 claims description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 6
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 4
- HJRDNARELSKHEF-CLFAGFIQSA-N 2-[2-[(z)-octadec-9-enoyl]oxyethoxy]ethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOCCOC(=O)CCCCCCC\C=C/CCCCCCCC HJRDNARELSKHEF-CLFAGFIQSA-N 0.000 claims description 4
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims description 4
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 4
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 4
- IYFATESGLOUGBX-YVNJGZBMSA-N Sorbitan monopalmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O IYFATESGLOUGBX-YVNJGZBMSA-N 0.000 claims description 4
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims description 4
- 239000004147 Sorbitan trioleate Substances 0.000 claims description 4
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 4
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 4
- 229940093471 ethyl oleate Drugs 0.000 claims description 4
- 229940068939 glyceryl monolaurate Drugs 0.000 claims description 4
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 4
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- GIPDEPRRXIBGNF-KTKRTIGZSA-N oxolan-2-ylmethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC1CCCO1 GIPDEPRRXIBGNF-KTKRTIGZSA-N 0.000 claims description 4
- 125000006353 oxyethylene group Chemical group 0.000 claims description 4
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims description 4
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims description 4
- 229940101027 polysorbate 40 Drugs 0.000 claims description 4
- 229940113124 polysorbate 60 Drugs 0.000 claims description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims description 4
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims description 4
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 claims description 4
- 235000011071 sorbitan monopalmitate Nutrition 0.000 claims description 4
- 239000001570 sorbitan monopalmitate Substances 0.000 claims description 4
- 229940031953 sorbitan monopalmitate Drugs 0.000 claims description 4
- 239000001587 sorbitan monostearate Substances 0.000 claims description 4
- 235000011076 sorbitan monostearate Nutrition 0.000 claims description 4
- 229940035048 sorbitan monostearate Drugs 0.000 claims description 4
- 235000019337 sorbitan trioleate Nutrition 0.000 claims description 4
- 229960000391 sorbitan trioleate Drugs 0.000 claims description 4
- 239000001589 sorbitan tristearate Substances 0.000 claims description 4
- 235000011078 sorbitan tristearate Nutrition 0.000 claims description 4
- 229960004129 sorbitan tristearate Drugs 0.000 claims description 4
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 229940072958 tetrahydrofurfuryl oleate Drugs 0.000 claims description 4
- NBMKJKDGKREAPL-CXSFZGCWSA-N (8s,9r,10s,11s,13s,14s,16r,17r)-9-chloro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-CXSFZGCWSA-N 0.000 claims description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 3
- ZESRJSPZRDMNHY-YFWFAHHUSA-N 11-deoxycorticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 ZESRJSPZRDMNHY-YFWFAHHUSA-N 0.000 claims description 3
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims description 3
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims description 3
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims description 3
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 claims description 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 3
- POPFMWWJOGLOIF-XWCQMRHXSA-N Flurandrenolide Chemical compound C1([C@@H](F)C2)=CC(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O POPFMWWJOGLOIF-XWCQMRHXSA-N 0.000 claims description 3
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 3
- MKPDWECBUAZOHP-AFYJWTTESA-N Paramethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O MKPDWECBUAZOHP-AFYJWTTESA-N 0.000 claims description 3
- 229960002478 aldosterone Drugs 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 229960004436 budesonide Drugs 0.000 claims description 3
- 229960003728 ciclesonide Drugs 0.000 claims description 3
- 229960004544 cortisone Drugs 0.000 claims description 3
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 claims description 3
- 229960003662 desonide Drugs 0.000 claims description 3
- 229960002593 desoximetasone Drugs 0.000 claims description 3
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 claims description 3
- 229960003654 desoxycortone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 3
- 229960004511 fludroxycortide Drugs 0.000 claims description 3
- 229960003469 flumetasone Drugs 0.000 claims description 3
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 claims description 3
- 229960000676 flunisolide Drugs 0.000 claims description 3
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 claims description 3
- 229960000890 hydrocortisone Drugs 0.000 claims description 3
- 229960001810 meprednisone Drugs 0.000 claims description 3
- PIDANAQULIKBQS-RNUIGHNZSA-N meprednisone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)CC2=O PIDANAQULIKBQS-RNUIGHNZSA-N 0.000 claims description 3
- 229960004584 methylprednisolone Drugs 0.000 claims description 3
- 229960001664 mometasone Drugs 0.000 claims description 3
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 claims description 3
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 3
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 3
- 229960002858 paramethasone Drugs 0.000 claims description 3
- 229960005205 prednisolone Drugs 0.000 claims description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims description 3
- 229960004618 prednisone Drugs 0.000 claims description 3
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 3
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 3
- 239000001488 sodium phosphate Substances 0.000 claims description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 239000011148 porous material Substances 0.000 claims description 2
- 239000001103 potassium chloride Substances 0.000 claims description 2
- 235000011164 potassium chloride Nutrition 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims 1
- 208000006673 asthma Diseases 0.000 abstract description 8
- 208000023504 respiratory system disease Diseases 0.000 abstract description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract description 6
- 230000000414 obstructive effect Effects 0.000 abstract description 6
- 239000013543 active substance Substances 0.000 description 13
- 238000004659 sterilization and disinfection Methods 0.000 description 11
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000010419 fine particle Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 4
- 238000000265 homogenisation Methods 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940125389 long-acting beta agonist Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 229940127211 short-acting beta 2 agonist Drugs 0.000 description 2
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical class C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102100038199 Desmoplakin Human genes 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical group CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940075564 anhydrous dibasic sodium phosphate Drugs 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229960001469 fluticasone furoate Drugs 0.000 description 1
- XTULMSXFIHGYFS-VLSRWLAYSA-N fluticasone furoate Chemical group O([C@]1([C@@]2(C)C[C@H](O)[C@]3(F)[C@@]4(C)C=CC(=O)C=C4[C@@H](F)C[C@H]3[C@@H]2C[C@H]1C)C(=O)SCF)C(=O)C1=CC=CO1 XTULMSXFIHGYFS-VLSRWLAYSA-N 0.000 description 1
- 238000011194 good manufacturing practice Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229920001684 low density polyethylene Polymers 0.000 description 1
- 239000004702 low-density polyethylene Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000011164 primary particle Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Definitions
- the invention relates to a process for the preparation of sterilized suspensions to be used in pharmaceutical formulations for inhalation by nebulization which is used in the treatment of chronic obstructive pulmonary disease (COPD), asthma and other obstructive respiratory diseases.
- COPD chronic obstructive pulmonary disease
- Obstructive lung disease is a significant public health problem. Asthma, chronic obstructive pulmonary disease (COPD) and other obstructive airway diseases are highly prevalent chronic diseases in the general population. These obstructive airway illnesses are manifested with chronic inflammation affecting the whole respiratory tract. Obstruction is usually intermittent and reversible in asthma but is progressive and irreversible in COPD.
- COPD chronic obstructive pulmonary disease
- nebulizers One alternative of MDI or DPI is the development of nebulizers in which aqueous solutions of pharmacologically-active substances are sprayed under high pressure so as to produce a mist of inhalable particles. Drugs combine pharmacologic activity with pharmaceutical properties. Desirable performance characteristics expected from them are physical and chemical stability, ease of processing, accurate and reproducible delivery to the target organ, and availability at the site of action.
- compositions for inhalation used in the treatment of obstructive respiratory diseases can comprise various active agents such as long acting muscarinic antagonists (LAMA), long acting beta agonists (LABA), short acting beta-2 agonists (SABA) and glucocorti costeroids.
- LAMA long acting muscarinic antagonists
- LABA long acting beta agonists
- SABA short acting beta-2 agonists
- glucocorti costeroids glucocorti costeroids
- Glucocorticosteroids are a class of drug that lowers inflammation in the body. Inhaled glucocorticosteroids reduce inflammation in the airways that carry air to the lungs (bronchial tubes) and reduce the mucus made by the bronchial tubes which makes easier to breathe.
- glucocorticosteroids such as ciclesonide, budesonide, fluticasone, aldosterone, beklometazone, betametazone, chloprednol, cortisone, cortivasole, deoxycortone, desonide, desoxymetasone, dexametasone, difluorocortolone, fluchlorolone, flumetasone, flunisolide, fluquinolone, fluquinonide, flurocortisone, fluorocortolone, flurometolone, flurandrenolone, halcynonide, hydrocortisone, icometasone, meprednisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tixocortole, triamcynol
- Fluticasone is the most commonly used glucocorticosteroid for inhalation.
- Fluticasone Propionate is the propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, anti-inflammatory and antipruritic effects.
- Fluticasone propionate sold under the brand name Flixotide, is a steroid medication.
- Sterilization is necessary for the complete destruction or removal of all microorganisms that could contaminate pharmaceuticals or other materials and thereby constitute a health hazard.
- the efficacy of any sterilization process will depend on the nature of the product, the extent and type of any contamination, and the conditions under which the final product has been prepared. The requirements for Good Manufacturing Practice should be observed throughout all stages of manufacture and sterilization. (The International Pharmacopoeia - Ninth Edition, 2019 5.8 Methods of sterilization)
- Physical methods include a sun-light method, heat methods (dry heat which includes red heat, flaming, incineration, hot air oven, infra-red and moist heat which includes below 100oC, at 100oC, above 100oC), vibration methods, filtration methods and radiation methods.
- Moist heat is the most commonly used technique used as disinfects, sanitize, sterilize and pasteurize. Moist heat is more effective in microbial control than dry heat because water is a better conductor of heat than air. Moist heat includes boiling, autoclaving, pasteurization and ultra-high temperature sterilization. The most resistant bacterial endospores can be killed through moist heat sterilization. Moist heat takes less time and results in a better outcome of sterilization.
- US5993781A relates to improvements in or relating to pharmaceutical compositions comprising a fluticasone ester.
- the invention relates to novel formulations of use in the administration of fluticasone propionate by inhalation but does not contain any teaching as to how to prepare the relevant pharmaceutical formulations in the form of suspensions.
- WO 99/25359 relates to a process for sterilizing corticosteroids by heating them at lower temperatures than those reported in some Pharmacopoeias (110-130°C vs 140-180°C) but does not contain any teaching as to how to prepare the relevant pharmaceutical formulations in the form of suspensions.
- EP3299013A1 provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time.
- dispersing or suspending agents used in a certain order in the process steps and their weight ratio are important in terms of increased stability, enhanced fine particle dose, fine particle fraction, delivery rate and total active agent values.
- the main object of the present invention is to provide a production method for preparing sterilized pharmaceutical glucocorticosteroid compositions for inhalation which eliminates all aforesaid problems and brings additional advantages to the relevant prior art.
- Another object of the present invention is to provide a process for the preparation of sterilized suspensions to be used in pharmaceutical formulations for inhalation by nebulization for use in the prevention, treatment, or in the alleviation of the symptoms of respiratory diseases, particularly asthma and chronic obstructive pulmonary disease.
- Another object of the present invention is to provide a process for the preparation of sterilized suspensions to be used in pharmaceutical formulations for inhalation by nebulization with increased stability, enhanced fine particle dose (FPD), fine particle fraction (FPF), delivery rate and total active agent values.
- Another object of the present invention is to provide a process for the preparation of sterilized suspensions to be used in pharmaceutical formulations for inhalation by nebulization with enhanced uniformity and homogeneity.
- Another object of the present invention is to obtain sterilized suspensions provided by the above-mentioned process comprising glucocorticosteroids.
- a further object of the present invention is to obtain sterilized suspensions comprising a glucocorti costeroid.
- Another object of the present invention is to obtain inhalation compositions comprising fluticasone or a pharmaceutically acceptable salt thereof.
- Another object of the present invention is to obtain sterilized suspension compositions comprising glucocorticosteroids, isotonic agents, buffering agents, dispersing or suspending agents.
- Another object of the present invention is to produce a much lower level of total impurities than the prior art sterilizations.
- Another object of the present invention is to describe a process for forming suspension and solution-type inhaler formulations to be delivered to the patient via nebulization.
- Another object of the present invention is to access of inhaler formulations to the lungs is achieved.
- Another object of the invention is to show how changes made in the process steps of the drug formulation improve the process in order to ensure effective delivery of the active substance.
- the two mixtures should be prepared in different mixing vessels.
- the mentioned mixtures are named as Mixture 1 and Mixture 2.
- These mixtures have different process steps.
- the dispersing or suspending agents used in the process steps and their ratio to each other are important in terms of increased stability, enhanced fine particle dose (FPD), fine particle fraction (FPF), delivery rate and total active agent values.
- FPD enhanced fine particle dose
- FPF fine particle fraction
- delivery rate delivery rate
- total active agent values In addition to the weight ratio of the dispersing or suspending agents, the temperature of the addition of the dispersing or suspending agents to the process is also important in order to achieve the desired quality profile.
- BFS Low fill seal
- LDPE pellets are placed in the machine, ampoules are formed with heat and air in the filling machine. And the ampoules are sealed with heat and air without leaving the filling machine.
- the present invention relates to a process for the preparation of sterilized suspensions to be used in pharmaceutical formulations for inhalation by nebulization, which comprises the following steps: a- obtaining Mixture 1 by:
- the heating is performed in the step numbered a) (i), (ii) and b) (i), (ii).
- the reason for heating is to increase the solubility/distribution of the excipients to be added.
- the temperature of the mixture in the step numbered a) (i), (ii) and b) (i), (ii) is 45°C-55°C.
- anc c is 200-2000 rpm, preferably 300-1800 rpm, more preferably 400-1500 rpm.
- Another important factor is the preparation of a suitable dispersing medium by including the dispersing or suspending agents in the process before the active agents to help disperse the active agents that is insoluble in water.
- the main purpose of dispersing a powder in a liquid is to separate primary particles from aggregates and agglomerates and then stabilize them in the liquid medium. This requires an effective dispersing or suspending agent that adsorbs very quickly at the solid/liquid interface.
- the main criterion for an effective dispersing or suspending agent is strong adsorption or attachment to the particle surface. This requires the dispersing or suspending agent to be attached to the active agent particle surface at multiple points.
- dispersing or suspending agent in suspension is to reduce the surface energy of the powder. This facilitates the decomposition and homogeneous dispersion stages of the agglomerates of the particles in the subsequent homogenization.
- the desired quality profile was achieved when the second dispersing or suspending agent was added.
- the second dispersing or suspending agent alone could not provide the medium to suspend the active agent, the desired quality profile was achieved when the first dispersing or suspending agent was added.
- the inventors have surprisingly been found that when the first dispersing or suspending agent and the second dispersing or suspending agent are added to the mixture together, a homogeneous final product can be obtained.
- One of the most important factors that lead to the desired quality profile is the weight ratio of the first dispersing or suspending agent to the second dispersing or suspending agent.
- the first dispersing or suspending agent is selected from the group comprising polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate or Twen20), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate (SpanR85), sorbitan mono-oleate, polyoxyethylene (20) sorbitan monooleate, natural lecithin, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene
- the first dispersing or suspending agent is polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate or Twen20).
- the second dispersing or suspending agent is selected from the group comprising sorbitan monolaurate (span20), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate (SpanR85), sorbitan mono-oleate, polyoxyethylene (20) sorbitan monooleate, natural lecithin, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, block copolymers of oxyethylene and oxypropylene, synthetic lecithin, diethylene glycol dioleate, tetrahydrofurfuryl oleate, ethy
- the second dispersing or suspending agent is sorbitan monolaurate (span20).
- the cooling step is performed in the step numbered a) (iii) of the process.
- the temperature of the mixture in the step numbered a) (iii) is 30°C- 40°C.
- the active agent is selected glucocorticosteroid or pharmaceutically acceptable salt thereof.
- the glucocorticosteroid is selected from the group comprising ciclesonide, budesonide, fluticasone, aldosterone, beklometazone, betametazone, chloprednol, cortisone, cortivasole, deoxycortone, desonide, desoxymetasone, dexametasone, difluorocortolone, fluchlorolone, flumetasone, flunisolide, fluquinolone, fluquinonide, flurocortisone, fluorocortolone, flurometolone, flurandrenolone, halcynonide, hydrocortisone, icometasone, meprednisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tixocortole, triamcynolondane or mixtures thereof.
- the glucocorticosteroids is fluticasone.
- the fluticasone salt is fluticasone furoate.
- the rotational speed in the step numbered (v) is 3000- 15000 rpm, preferably 3000-13000 rpm, more preferably 3000-10000 rpm.
- the liquid pharmaceutical composition typically comprises isotonic agents.
- the isotonic agents may be any pharmaceutically acceptable isotonic agents. Suspensions will desirably be isotonic.
- the formulations which are used present process may be adjusted to desired isotonicity by the addition of suitable isotonic agents.
- the isotonic agent in the step numbered b) (ii) is selected from the group comprising mannitol, sodium chloride, potassium chloride and sodium bromide or a pharmaceutically acceptable salt thereof.
- the isotonic agents in the step numbered b) (ii) is sodium chloride.
- the liquid pharmaceutical composition comprises one or more buffering agents.
- the buffering agents are pharmaceutically acceptable buffering agents.
- the buffering agents may be any buffering agents suitable for use in a liquid pharmaceutical composition suitable for inhalation.
- One or more buffering agents are typically selected from citrate or phosphate buffers.
- Citrate buffers is selected from the group comprising citric acid, sodium citrate and mixtures thereof.
- Phosphate buffers is selected from the group comprising phosphoric acid, monosodium phosphate, dibasic sodium phosphate and mixtures thereof.
- the pharmaceutical composition comprises at least two buffering agents in the present invention.
- the buffering agents is selected from the group comprising citric acid, sodium citrate, phosphoric acid, monosodium phosphate, dibasic sodium phosphate and mixtures thereof.
- the buffering agents in the step numbered (ii) are monosodium phosphate dihydrate and dibasic sodium phosphate anhydrous.
- the applied process steps have a direct effect on the blend uniformity, which is one of the first chemical indicators of the product's quality profile. It has been observed that if the above steps are not followed and are added only one dispersing or suspending agent into the present process, the blend uniformity cannot be achieved.
- the filtration process in the step numbered b) (iii) is carried out by filtering through 0.45 micron + 0.2 micron pore diameter membrane filter.
- compositions subjected to the invention are prepared by these steps: a- obtaining Mixture 1 by:
- the invention also defines sterilized suspension compositions obtained by the process subjected to the invention.
- a sterilized suspension composition comprises a glucocorticosteroid or pharmaceutically acceptable salt thereof.
- a sterilized suspension composition comprises fluticasone propionate.
- a sterilized suspension composition comprising glucocorticosteroids, isotonic agents, buffering agents, dispersing or suspending agents.
- the amount of polysorbate 20 is between 0-1.0 % by weight of the total composition.
- the amount of sorbitan monolaurate is between 0-0.3 % by weight of the total composition.
- the amount of monosodium phosphate dihydrate is between 0- 2 % by weight of the total composition.
- the amount of dibasic sodium phosphate anhydrous is between 0-1 % by weight of the total composition.
- the amount of sodium chloride is between 0-0.9 % by weight of the total composition.
- the concentration of active agents in the pharmaceutical composition is 1 mg/1 ml_, 0.25 mg/1 ml_, 2 mg/2 ml_ and 0.5 mg/2 ml_.
- the process for sterilized suspension composition for nebulization subjected to the invention comprises;
- Example 1 the below-given formulations can be used process for preparing a sterilized suspension composition subjected to the invention.
- a sterilized suspension composition subjected to the invention is used in the treatment of the respiratory diseases selected from asthma and chronic obstructive pulmonary disease and other obstructive respiratory diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a process for the preparation of a sterilized suspension to be used in pharmaceutical formulations for inhalation by nebulization which is used in the treatment of chronic obstructive pulmonary disease (COPD), asthma and other obstructive respiratory diseases.
Description
PROCESS FOR THE PREPARATION OF STERILIZED SUSPENSIONS FOR THE
INHALATION BY NEBULIZATION
Field of Invention
The invention relates to a process for the preparation of sterilized suspensions to be used in pharmaceutical formulations for inhalation by nebulization which is used in the treatment of chronic obstructive pulmonary disease (COPD), asthma and other obstructive respiratory diseases.
Priority Claims and Related Applications
This application claims the benefit of PCT application Nos. PCT/TR2021/050408 and PCT/TR2021/050409, all filed April 29, 2021, the entire content of which is incorporated by reference herein in its entirety.
The background of the invention
Obstructive lung disease is a significant public health problem. Asthma, chronic obstructive pulmonary disease (COPD) and other obstructive airway diseases are highly prevalent chronic diseases in the general population. These obstructive airway illnesses are manifested with chronic inflammation affecting the whole respiratory tract. Obstruction is usually intermittent and reversible in asthma but is progressive and irreversible in COPD.
People who are suffering from these airway diseases may be treated with medications such as corticosteroids, which are administered via metered-dose inhalers or dry powder inhalers. However, certain patient populations, e.g., neurologically impaired, elderly, or pediatric asthmatics, may lack the breath coordination needed for metered-dose inhalers or lack the lung capacity needed to use DPIs. Thus, these asthma patients require the administration of therapy via nebulizers. One alternative of MDI or DPI is the development of nebulizers in which aqueous solutions of pharmacologically-active substances are sprayed under high pressure so as to produce a mist of inhalable particles.
Drugs combine pharmacologic activity with pharmaceutical properties. Desirable performance characteristics expected from them are physical and chemical stability, ease of processing, accurate and reproducible delivery to the target organ, and availability at the site of action.
Pharmaceutical compositions for inhalation used in the treatment of obstructive respiratory diseases can comprise various active agents such as long acting muscarinic antagonists (LAMA), long acting beta agonists (LABA), short acting beta-2 agonists (SABA) and glucocorti costeroids.
Glucocorticosteroids are a class of drug that lowers inflammation in the body. Inhaled glucocorticosteroids reduce inflammation in the airways that carry air to the lungs (bronchial tubes) and reduce the mucus made by the bronchial tubes which makes easier to breathe.
Among the various types of drug which are administered by inhalation for the treatment of the pulmonary diseases, glucocorticosteroids, such as ciclesonide, budesonide, fluticasone, aldosterone, beklometazone, betametazone, chloprednol, cortisone, cortivasole, deoxycortone, desonide, desoxymetasone, dexametasone, difluorocortolone, fluchlorolone, flumetasone, flunisolide, fluquinolone, fluquinonide, flurocortisone, fluorocortolone, flurometolone, flurandrenolone, halcynonide, hydrocortisone, icometasone, meprednisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tixocortole, triamcynolondane or mixtures thereof. They are generally administered in suspension, in an aqueous phase that usually also contains one or more pharmaceutically acceptable excipients, such as dispersing and/or suspending agents, isotonic and/or buffering agents, or in a propellant.
Fluticasone is the most commonly used glucocorticosteroid for inhalation. Fluticasone Propionate is the propionate salt form of fluticasone, a synthetic trifluorinated glucocorticoid receptor agonist with antiallergic, anti-inflammatory and antipruritic effects. Fluticasone propionate, sold under the brand name Flixotide, is a steroid medication.
In order to ensure an effective and safe penetration into the low respiratory tract of the patient, i.e. bronchioli and alveoli, one of the most important parameters that must be met by pharmaceutical formulations for inhalation is sterility. This requirement is becoming more and more mandatory as confirmed by the FDA final rule "Sterility Requirement for Aqueous-Based Drug Products for Oral Inhalation" published in the Federal Register of May 26, 2000 (65 FR 34082) governing the quality and safety of pharmaceutical products for a number of reasons,
including the fact that the lungs are a particularly vulnerable organ of the human body, and many patients who use inhaled drugs have general health problems.
Sterilization is necessary for the complete destruction or removal of all microorganisms that could contaminate pharmaceuticals or other materials and thereby constitute a health hazard. The efficacy of any sterilization process will depend on the nature of the product, the extent and type of any contamination, and the conditions under which the final product has been prepared. The requirements for Good Manufacturing Practice should be observed throughout all stages of manufacture and sterilization. (The International Pharmacopoeia - Ninth Edition, 2019 5.8 Methods of sterilization)
There are two types of sterilization can be used to manufacture sterile pharmaceutical formulations for inhalation: chemical and physical. Chemical sterilization, for the most part, has been based on exposure to toxic compounds, for example, formaldehyde, ethylene oxide. However, when used to sterilize glucocorticosteroids, ethylene oxide has been found to leave residual amounts of ethylene oxide in the drug preparation. Ethylene oxide leaves a toxic residue, flammable explosive, carcinogenic, and has been found that the residual levels are often above the pharmaceutically acceptable limits as set by most regulatory agencies.
Physical methods include a sun-light method, heat methods (dry heat which includes red heat, flaming, incineration, hot air oven, infra-red and moist heat which includes below 100oC, at 100oC, above 100oC), vibration methods, filtration methods and radiation methods.
Moist heat is the most commonly used technique used as disinfects, sanitize, sterilize and pasteurize. Moist heat is more effective in microbial control than dry heat because water is a better conductor of heat than air. Moist heat includes boiling, autoclaving, pasteurization and ultra-high temperature sterilization. The most resistant bacterial endospores can be killed through moist heat sterilization. Moist heat takes less time and results in a better outcome of sterilization.
US5993781A relates to improvements in or relating to pharmaceutical compositions comprising a fluticasone ester. In particular the invention relates to novel formulations of use in the administration of fluticasone propionate by inhalation but does not contain any teaching as to how to prepare the relevant pharmaceutical formulations in the form of suspensions.
WO 99/25359 relates to a process for sterilizing corticosteroids by heating them at lower temperatures than those reported in some Pharmacopoeias (110-130°C vs 140-180°C) but
does not contain any teaching as to how to prepare the relevant pharmaceutical formulations in the form of suspensions.
EP3299013A1 provides a method for the sterilization of a labile glucocorticosteroid, which method comprises heat-treating by moist heat the labile glucocorticosteroid in the form of a suspension for a sterilizing-effective time.
As seen above, there are various processes for producing sterile pharmaceutical formulations for inhalation. The dispersing or suspending agents used in a certain order in the process steps and their weight ratio are important in terms of increased stability, enhanced fine particle dose, fine particle fraction, delivery rate and total active agent values.
The steps of adding dispersing or suspending agents used in the process to the process and their weight ratios of applied are of great importance in order to ensure homogenization and prevent losses in the process.
Considering the state of art, it can be seen that the prior art has not put enough emphasis on alternative solutions for this problem. Thus, there is still a need for innovative processes that will solve the homogenization problem, and which will provide a standardized method for the fast, robust and reproducible production of stable homogeneous suspension inhalation compositions with enhanced FPF, delivery rate and total active ingredient values.
Objects and Brief Description of the Invention
The main object of the present invention is to provide a production method for preparing sterilized pharmaceutical glucocorticosteroid compositions for inhalation which eliminates all aforesaid problems and brings additional advantages to the relevant prior art.
Another object of the present invention is to provide a process for the preparation of sterilized suspensions to be used in pharmaceutical formulations for inhalation by nebulization for use in the prevention, treatment, or in the alleviation of the symptoms of respiratory diseases, particularly asthma and chronic obstructive pulmonary disease.
Another object of the present invention is to provide a process for the preparation of sterilized suspensions to be used in pharmaceutical formulations for inhalation by nebulization with increased stability, enhanced fine particle dose (FPD), fine particle fraction (FPF), delivery rate and total active agent values.
Another object of the present invention is to provide a process for the preparation of sterilized suspensions to be used in pharmaceutical formulations for inhalation by nebulization with enhanced uniformity and homogeneity.
Another object of the present invention is to obtain sterilized suspensions provided by the above-mentioned process comprising glucocorticosteroids.
A further object of the present invention is to obtain sterilized suspensions comprising a glucocorti costeroid.
Another object of the present invention is to obtain inhalation compositions comprising fluticasone or a pharmaceutically acceptable salt thereof.
Another object of the present invention is to obtain sterilized suspension compositions comprising glucocorticosteroids, isotonic agents, buffering agents, dispersing or suspending agents.
Another object of the present invention is to produce a much lower level of total impurities than the prior art sterilizations.
Another object of the present invention is to describe a process for forming suspension and solution-type inhaler formulations to be delivered to the patient via nebulization.
Another object of the present invention is to access of inhaler formulations to the lungs is achieved.
Another object of the invention is to show how changes made in the process steps of the drug formulation improve the process in order to ensure effective delivery of the active substance.
Detailed description of the invention
In accordance with the objects outlined above, detailed features of the present invention are given herein.
In order to implement the invention, firstly, the two mixtures should be prepared in different mixing vessels. The mentioned mixtures are named as Mixture 1 and Mixture 2. These
mixtures have different process steps. The dispersing or suspending agents used in the process steps and their ratio to each other are important in terms of increased stability, enhanced fine particle dose (FPD), fine particle fraction (FPF), delivery rate and total active agent values. In addition to the weight ratio of the dispersing or suspending agents, the temperature of the addition of the dispersing or suspending agents to the process is also important in order to achieve the desired quality profile. These two mixtures are mixed and filled to the nebul vials. BFS (Blow fill seal) technology is used for filling in the present invention. In this technology, LDPE pellets are placed in the machine, ampoules are formed with heat and air in the filling machine. And the ampoules are sealed with heat and air without leaving the filling machine.
The present invention relates to a process for the preparation of sterilized suspensions to be used in pharmaceutical formulations for inhalation by nebulization, which comprises the following steps: a- obtaining Mixture 1 by:
(i) mixing the water for injection
(ii) adding respectively the first dispersing or suspending agent, the second dispersing or suspending agent and mixing
(iii) cooling the mixture obtained
(iv) adding glucocorticosteroid and mixing
(v) homogenizing the mixture in the homogenizer
(vi) sterilizing the homogeneous suspension with the autoclaving b- obtaining Mixture 2 by:
(i) mixing the water for injection
(ii) adding respectively isotonic agent, and at least two buffering agents, and mixing
(iii) performing the filtration process c- mixing the Mixture 1 and Mixture 2 wherein the weight ratio of first dispersing or suspending agent to second dispersing or suspending agent is 20:1, preferably 15:1 , more preferably 10:1.
The heating is performed in the step numbered a) (i), (ii) and b) (i), (ii). The reason for heating is to increase the solubility/distribution of the excipients to be added. According to one embodiment, the temperature of the mixture in the step numbered a) (i), (ii) and b) (i), (ii) is 45°C-55°C.
According to one embodiment, the rotational speed in the step numbered a) (i), (ii), (iii), (iv), b)
(1), (ii) anc c is 200-2000 rpm, preferably 300-1800 rpm, more preferably 400-1500 rpm.
Another important factor is the preparation of a suitable dispersing medium by including the dispersing or suspending agents in the process before the active agents to help disperse the active agents that is insoluble in water.
The main purpose of dispersing a powder in a liquid is to separate primary particles from aggregates and agglomerates and then stabilize them in the liquid medium. This requires an effective dispersing or suspending agent that adsorbs very quickly at the solid/liquid interface. The main criterion for an effective dispersing or suspending agent is strong adsorption or attachment to the particle surface. This requires the dispersing or suspending agent to be attached to the active agent particle surface at multiple points.
In addition, another role of the dispersing or suspending agent in suspension is to reduce the surface energy of the powder. This facilitates the decomposition and homogeneous dispersion stages of the agglomerates of the particles in the subsequent homogenization.
Although the first dispersing or suspending agent alone could not provide the medium to suspend the active agent, the desired quality profile was achieved when the second dispersing or suspending agent was added. Likewise, although the second dispersing or suspending agent alone could not provide the medium to suspend the active agent, the desired quality profile was achieved when the first dispersing or suspending agent was added. The inventors have surprisingly been found that when the first dispersing or suspending agent and the second dispersing or suspending agent are added to the mixture together, a homogeneous final product can be obtained. One of the most important factors that lead to the desired quality profile is the weight ratio of the first dispersing or suspending agent to the second dispersing or suspending agent.
According to the one embodiment, the first dispersing or suspending agent is selected from the group comprising polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate or Twen20), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate (SpanR85), sorbitan mono-oleate, polyoxyethylene (20) sorbitan monooleate, natural lecithin, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene
(2) ether, lauryl polyoxyethylene (4) ether, block copolymers of oxyethylene and oxypropylene,
synthetic lecithin, diethylene glycol dioleate, tetrahydrofurfuryl oleate, ethyl oleate, glyceryl mono-oleate, polyethylene glycol 400 and glyceryl monolaurate or mixtures thereof.
According to the preferred embodiment, the first dispersing or suspending agent is polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate or Twen20).
According to the one embodiment, the second dispersing or suspending agent is selected from the group comprising sorbitan monolaurate (span20), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate (SpanR85), sorbitan mono-oleate, polyoxyethylene (20) sorbitan monooleate, natural lecithin, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, block copolymers of oxyethylene and oxypropylene, synthetic lecithin, diethylene glycol dioleate, tetrahydrofurfuryl oleate, ethyl oleate, glyceryl mono-oleate, polyethylene glycol 400 and glyceryl monolaurate or mixtures thereof.
According to the preferred embodiment, the second dispersing or suspending agent is sorbitan monolaurate (span20).
The cooling step is performed in the step numbered a) (iii) of the process. According to the preferred embodiment, the temperature of the mixture in the step numbered a) (iii) is 30°C- 40°C.
According to the preferred embodiment, the active agent is selected glucocorticosteroid or pharmaceutically acceptable salt thereof.
In a preferred embodiment of the invention, the glucocorticosteroid is selected from the group comprising ciclesonide, budesonide, fluticasone, aldosterone, beklometazone, betametazone, chloprednol, cortisone, cortivasole, deoxycortone, desonide, desoxymetasone, dexametasone, difluorocortolone, fluchlorolone, flumetasone, flunisolide, fluquinolone, fluquinonide, flurocortisone, fluorocortolone, flurometolone, flurandrenolone, halcynonide, hydrocortisone, icometasone, meprednisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tixocortole, triamcynolondane or mixtures thereof.
According to the preferred embodiment, the glucocorticosteroids is fluticasone. According to this preferred embodiment, the fluticasone salt is fluticasone furoate.
According to the preferred embodiment, the rotational speed in the step numbered (v) is 3000- 15000 rpm, preferably 3000-13000 rpm, more preferably 3000-10000 rpm.
The liquid pharmaceutical composition typically comprises isotonic agents. The isotonic agents may be any pharmaceutically acceptable isotonic agents. Suspensions will desirably be isotonic. The formulations which are used present process may be adjusted to desired isotonicity by the addition of suitable isotonic agents.
According to a preferred embodiment, the isotonic agent in the step numbered b) (ii) is selected from the group comprising mannitol, sodium chloride, potassium chloride and sodium bromide or a pharmaceutically acceptable salt thereof.
According to the preferred embodiment, the isotonic agents in the step numbered b) (ii) is sodium chloride.
Typically, the liquid pharmaceutical composition comprises one or more buffering agents. The buffering agents are pharmaceutically acceptable buffering agents. The buffering agents may be any buffering agents suitable for use in a liquid pharmaceutical composition suitable for inhalation. One or more buffering agents are typically selected from citrate or phosphate buffers. Citrate buffers is selected from the group comprising citric acid, sodium citrate and mixtures thereof. Phosphate buffers is selected from the group comprising phosphoric acid, monosodium phosphate, dibasic sodium phosphate and mixtures thereof.
According to one embodiment, the pharmaceutical composition comprises at least two buffering agents in the present invention.
According to one embodiment, the buffering agents is selected from the group comprising citric acid, sodium citrate, phosphoric acid, monosodium phosphate, dibasic sodium phosphate and mixtures thereof.
According to the preferred embodiment, the buffering agents in the step numbered (ii) are monosodium phosphate dihydrate and dibasic sodium phosphate anhydrous.
The applied process steps have a direct effect on the blend uniformity, which is one of the first chemical indicators of the product's quality profile. It has been observed that if the above steps
are not followed and are added only one dispersing or suspending agent into the present process, the blend uniformity cannot be achieved.
The steps of adding dispersing or suspending agents and their weight ratios of great importance in order to ensure homogenization and prevent losses in the process.
According to one embodiment, the filtration process in the step numbered b) (iii) is carried out by filtering through 0.45 micron + 0.2 micron pore diameter membrane filter.
According to one embodiment, the pharmaceutical compositions subjected to the invention are prepared by these steps: a- obtaining Mixture 1 by:
(i) mixing the water for injection
(ii) adding respectively polysorbate 20 (tween 20), sorbitan monolaurate (span 20) and mixing
(iii) cooling the obtained mixture
(iv) adding fluticasone propionate and mixing
(v) homogenizing the mixture in the homogenizer
(vi) sterilizing the homogeneous suspension with the autoclaving b- obtaining Mixture 2 by:
(i) mixing the water for injection
(ii) adding respectively sodium chloride, monosodium phosphate dihydrate and anhydrous dibasic sodium phosphate, and mixing
(iii) performing the filtration process c- mixing the Mixture 1 and Mixture 2 wherein the weight ratio of polysorbate 20 (tween 20) to sorbitan monolaurate (span 20) is 20:1 , preferably 15:1 , more preferably 10:1.
The invention also defines sterilized suspension compositions obtained by the process subjected to the invention.
According to the preferred embodiment, a sterilized suspension composition comprises a glucocorticosteroid or pharmaceutically acceptable salt thereof.
According to the preferred embodiment, a sterilized suspension composition comprises fluticasone propionate.
According to the preferred embodiment, a sterilized suspension composition comprising glucocorticosteroids, isotonic agents, buffering agents, dispersing or suspending agents.
According to one embodiment, the amount of polysorbate 20 is between 0-1.0 % by weight of the total composition.
According to one embodiment, the amount of sorbitan monolaurate is between 0-0.3 % by weight of the total composition.
According to one embodiment, the amount of monosodium phosphate dihydrate is between 0- 2 % by weight of the total composition.
According to one embodiment, the amount of dibasic sodium phosphate anhydrous is between 0-1 % by weight of the total composition.
According to one embodiment, the amount of sodium chloride is between 0-0.9 % by weight of the total composition.
According to one embodiment, the concentration of active agents in the pharmaceutical composition is 1 mg/1 ml_, 0.25 mg/1 ml_, 2 mg/2 ml_ and 0.5 mg/2 ml_.
According to one preferred embodiment, the process for sterilized suspension composition for nebulization subjected to the invention comprises;
- fluticasone propionate,
- polysorbate 20,
- sorbitan monolaurate,
- monosodium phosphate dihydrate,
- dibasic sodium phosphate anhydrous,
- sodium chloride,
- water for injection.
According to all these embodiments, the below-given formulations can be used process for preparing a sterilized suspension composition subjected to the invention. These examples are not limiting the scope of the present invention and should be considered under the light of the foregoing detailed disclosure.
Example 1 :
Example 2:
According to a preferred embodiment, a sterilized suspension composition subjected to the invention is used in the treatment of the respiratory diseases selected from asthma and chronic obstructive pulmonary disease and other obstructive respiratory diseases.
Claims
1. A process for the preparation of a sterilized suspension to be used in pharmaceutical formulations for inhalation by nebulization, which comprises the following steps: a- obtaining Mixture 1 by:
(i) mixing the water for injection
(ii) adding respectively the first dispersing or suspending agent, the second dispersing or suspending agent and mixing
(iii) cooling the mixture obtained
(iv) adding glucocorticosteroid and mixing
(v) homogenizing the mixture in the homogenizer
(vi) sterilizing the homogeneous suspension with the autoclaving b- obtaining Mixture 2 by:
(i) mixing the water for injection
(ii) adding respectively isotonic agent, and at least two buffering agents, and mixing
(iii) performing the filtration process c- mixing the Mixture 1 and Mixture 2 wherein the weight ratio of first dispersing or suspending agent to second dispersing or suspending agent is 20:1, preferably 15:1 , more preferably 10:1.
2. A process according to claim 1 , wherein the first dispersing or suspending agent is selected from the group comprising polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate or Twen20), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate (SpanR85), sorbitan mono-oleate, polyoxyethylene (20) sorbitan monooleate, natural lecithin, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, block copolymers of oxyethylene and oxypropylene, synthetic lecithin, diethylene glycol dioleate, tetrahydrofurfuryl oleate, ethyl oleate, glyceryl mono-oleate, polyethylene glycol 400 and glyceryl monolaurate or mixtures thereof.
3. A process according to claim 2, the first dispersing or suspending agent is polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate or Twen20).
4. A process according to claim 1, wherein the second dispersing or suspending agent is selected from the group comprising sorbitan monolaurate (span20), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), sorbitan monopalmitate, sorbitan monostearate, sorbitan tristearate, sorbitan monooleate, sorbitan trioleate (SpanR85), sorbitan mono-oleate, polyoxyethylene (20) sorbitan monooleate, natural lecithin, oleyl polyoxyethylene (2) ether, stearyl polyoxyethylene (2) ether, lauryl polyoxyethylene (4) ether, block copolymers of oxyethylene and oxypropylene, synthetic lecithin, diethylene glycol dioleate, tetrahydrofurfuryl oleate, ethyl oleate, glyceryl mono-oleate, polyethylene glycol 400 and glyceryl monolaurate or mixtures thereof.
5. A process according to claim 4, wherein the second dispersing or suspending agent is sorbitan monolaurate (span20).
6. A process according to any one of the proceeding claims, the first rotational speed is 200- 2000 rpm, preferably 300-1800 rpm, more preferably 400-1500 rpm.
7. A process according to any one of the proceeding claims, wherein the glucocorticosteroid is selected from the group comprising ciclesonide, budesonide, fluticasone, aldosterone, beklometazone, betametazone, chloprednol, cortisone, cortivasole, deoxycortone, desonide, desoxymetasone, dexametasone, difluorocortolone, fluchlorolone, flumetasone, flunisolide, fluquinolone, fluquinonide, flurocortisone, fluorocortolone, flurometolone, flurandrenolone, halcynonide, hydrocortisone, icometasone, meprednisone, methylprednisolone, mometasone, paramethasone, prednisolone, prednisone, tixocortole, triamcynolondane or mixtures thereof.
8. A process according to claim 5, wherein the glucocorticosteroid is fluticasone propionate.
9. A process according to any one of the proceeding claims, the second rotational speed is 3000-15000 rpm, preferably 3000-13000 rpm, more preferably 3000-10000 rpm.
10. A process according to any one of the proceeding claims, wherein the isotonic agent is selected from the group comprising mannitol, sodium chloride, potassium chloride and sodium bromide or a pharmaceutically acceptable salt thereof.
11. A process according to claim 8, the isotonic agent is sodium chloride.
12. A process according to any one of the proceeding claims, wherein buffering agents are selected from the group comprising citric acid, sodium citrate, phosphoric acid, monosodium phosphate, dibasic sodium phosphate and mixtures thereof.
13. A process according to claim 10, wherein buffering agents are monosodium phosphate dihydrate and dibasic sodium phosphate anhydrous.
14. A process according to any one of the proceeding claims, wherein the filtration process in the step numbered b) (iii) is carried out by filtering through 0.45 micron + 0.2 micron pore diameter PES capsule membrane filter.
15. A process according to any one of the proceeding claims, wherein the temperature of the mixture in the step numbered a) (i), (ii) and b) (i), (ii) is 45°C-55°C.
16. A process according to any one of the proceeding claims, wherein the temperature of the mixture in the step numbered a) (iii) is 30°C-40°C.
17. A process according to any one of the proceeding claims, wherein the temperature of the mixture in the step numbered a) (vi) is carried out at 121 °C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2021/050410 WO2022231533A1 (en) | 2021-04-29 | 2021-04-29 | Process for the preparation of sterilized suspensions for the inhalation by nebulization |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/TR2021/050410 WO2022231533A1 (en) | 2021-04-29 | 2021-04-29 | Process for the preparation of sterilized suspensions for the inhalation by nebulization |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022231533A1 true WO2022231533A1 (en) | 2022-11-03 |
Family
ID=83848692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/TR2021/050410 WO2022231533A1 (en) | 2021-04-29 | 2021-04-29 | Process for the preparation of sterilized suspensions for the inhalation by nebulization |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2022231533A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050175546A1 (en) * | 2002-04-17 | 2005-08-11 | Barbara Sambuco | Process for preparation of a sterile suspension of corticosteroid particles for the administration by inhalation |
| US20080269178A1 (en) * | 2004-11-16 | 2008-10-30 | John Miller | Pharmaceutical Manufacturing Process For Heat Sterilized Glucocorticoid Suspensions |
| US20160015634A1 (en) * | 2003-12-16 | 2016-01-21 | Takeda Gmbh | Aqueous suspensions of ciclesonide for nebulisation |
-
2021
- 2021-04-29 WO PCT/TR2021/050410 patent/WO2022231533A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050175546A1 (en) * | 2002-04-17 | 2005-08-11 | Barbara Sambuco | Process for preparation of a sterile suspension of corticosteroid particles for the administration by inhalation |
| US20160015634A1 (en) * | 2003-12-16 | 2016-01-21 | Takeda Gmbh | Aqueous suspensions of ciclesonide for nebulisation |
| US20080269178A1 (en) * | 2004-11-16 | 2008-10-30 | John Miller | Pharmaceutical Manufacturing Process For Heat Sterilized Glucocorticoid Suspensions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1126823B1 (en) | A process for the preparation of sterile therapeutically acceptable beclomethasone dipropionate | |
| JP4598268B2 (en) | New composition of matter | |
| US7541021B2 (en) | Process for preparation of a sterile suspension of corticosteroid particles for the administration by inhalation | |
| JP5001657B2 (en) | Aqueous suspension of ciclesonide for nebulization | |
| JP2009537570A (en) | Unit dose formulation with inhalable solution of albuterol | |
| WO2021068961A1 (en) | Inhalation solution pharmaceutical composition and preparation method therefor | |
| RU2611665C2 (en) | Improved composition of corticosteroid suspension for inhalation | |
| WO2022231533A1 (en) | Process for the preparation of sterilized suspensions for the inhalation by nebulization | |
| CN107106516A (en) | Pharmaceutical combination product | |
| WO2022231531A1 (en) | Process for the preparation of sterilized suspensions for the inhalation by nebulization | |
| TR2023013885T2 (en) | METHOD OF PREPARING STERILIZED SUSPENSIONS FOR INHALATION BY NEBULIZATION | |
| WO2022231532A1 (en) | Process for the preparation of sterilized suspensions for the inhalation by nebulization | |
| WO2022098321A1 (en) | Process for the preparation of sterilised suspensions for the administration by inhalation | |
| TR2023005107T2 (en) | METHOD FOR PREPARING STERILIZED SUSPENSIONS FOR USE BY INHALATION | |
| TR2023013883T2 (en) | METHOD OF PREPARING STERILIZED SUSPENSIONS FOR INHALATION BY NEBULIZATION | |
| WO2023136788A1 (en) | Process for the preparation of a sterile, homogeneous suspension for inhalation by nebulization | |
| WO2023136787A1 (en) | Process for the preparation of a sterile, homogeneous suspension for inhalation by nebulization | |
| WO2024025486A1 (en) | A process for the preparation of suspensions for inhalation by nebulization | |
| KR20230039894A (en) | Inhalable Pharmaceutical Composition Used For Preventing or Treating COVID-19 INFECTION DISEASE | |
| US20150290220A1 (en) | Pharmaceutical formualtions comprising a Gluococorticosteroid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21939506 Country of ref document: EP Kind code of ref document: A1 |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2023/013885 Country of ref document: TR |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 21939506 Country of ref document: EP Kind code of ref document: A1 |